These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34638943)

  • 1. Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress.
    Trnovska J; Svoboda P; Pelantova H; Kuzma M; Kratochvilova H; Kasperova BJ; Dvorakova I; Rosolova K; Malinska H; Huttl M; Markova I; Oliyarnyk O; Melcova M; Skop V; Mraz M; Stemberkova-Hubackova S; Haluzik M
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE
    Nasiri-Ansari N; Nikolopoulou C; Papoutsi K; Kyrou I; Mantzoros CS; Kyriakopoulos G; Chatzigeorgiou A; Kalotychou V; Randeva MS; Chatha K; Kontzoglou K; Kaltsas G; Papavassiliou AG; Randeva HS; Kassi E
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic cardio- and reno-protective effects of empagliflozin in a prediabetic rat model.
    Huttl M; Markova I; Miklankova D; Oliyarnyk O; Trnovska J; Kucera J; Sedlacek R; Haluzik M; Malinska H
    J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33475091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice.
    Obata A; Kubota N; Kubota T; Iwamoto M; Sato H; Sakurai Y; Takamoto I; Katsuyama H; Suzuki Y; Fukazawa M; Ikeda S; Iwayama K; Tokuyama K; Ueki K; Kadowaki T
    Endocrinology; 2016 Mar; 157(3):1029-42. PubMed ID: 26713783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
    Xu L; Nagata N; Nagashimada M; Zhuge F; Ni Y; Chen G; Mayoux E; Kaneko S; Ota T
    EBioMedicine; 2017 Jun; 20():137-149. PubMed ID: 28579299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia.
    Hüttl M; Markova I; Miklankova D; Zapletalova I; Poruba M; Haluzik M; Vaněčkova I; Malinska H
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
    Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB
    Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome.
    Kusaka H; Koibuchi N; Hasegawa Y; Ogawa H; Kim-Mitsuyama S
    Cardiovasc Diabetol; 2016 Nov; 15(1):157. PubMed ID: 27835975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet.
    Xu L; Nagata N; Chen G; Nagashimada M; Zhuge F; Ni Y; Sakai Y; Kaneko S; Ota T
    BMJ Open Diabetes Res Care; 2019; 7(1):e000783. PubMed ID: 31749970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats.
    Ala M; Khoshdel MRF; Dehpour AR
    Oxid Med Cell Longev; 2022; 2022():1197061. PubMed ID: 35126806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice.
    Huang CC; Chou CA; Chen WY; Yang JL; Lee WC; Chen JB; Lee CT; Li LC
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy.
    Castoldi G; Carletti R; Ippolito S; Colzani M; Barzaghi F; Stella A; Zerbini G; Perseghin G; Zatti G; di Gioia CRT
    Acta Diabetol; 2021 Aug; 58(8):1059-1070. PubMed ID: 33760995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice.
    Ganbaatar B; Fukuda D; Shinohara M; Yagi S; Kusunose K; Yamada H; Soeki T; Hirata KI; Sata M
    Eur J Pharmacol; 2020 May; 875():173040. PubMed ID: 32114052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carnitine supplementation alleviates lipid metabolism derangements and protects against oxidative stress in non-obese hereditary hypertriglyceridemic rats.
    Cahova M; Chrastina P; Hansikova H; Drahota Z; Trnovska J; Skop V; Spacilova J; Malinska H; Oliyarnyk O; Papackova Z; Palenickova E; Kazdova L
    Appl Physiol Nutr Metab; 2015 Mar; 40(3):280-91. PubMed ID: 25723909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet.
    Hojná S; Malínská H; Hüttl M; Vaňourková Z; Marková I; Miklánková D; Hrdlička J; Papoušek F; Neckář J; Kujal P; Behuliak M; Rauchová H; Kadlecová M; Sedmera D; Neffeová K; Zábrodská E; Olejníčková V; Zicha J; Vaněčková I
    Biomed Pharmacother; 2024 May; 174():116520. PubMed ID: 38581924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins.
    Park SH; Belcastro E; Hasan H; Matsushita K; Marchandot B; Abbas M; Toti F; Auger C; Jesel L; Ohlmann P; Morel O; Schini-Kerth VB
    Cardiovasc Diabetol; 2021 Mar; 20(1):65. PubMed ID: 33726768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial.
    Larsen EL; Cejvanovic V; Kjær LK; Vilsbøll T; Knop FK; Rungby J; Poulsen HE
    BMJ Open; 2017 May; 7(5):e014728. PubMed ID: 28490557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress.
    Petito-da-Silva TI; Souza-Mello V; Barbosa-da-Silva S
    Mol Cell Endocrinol; 2019 Dec; 498():110539. PubMed ID: 31419466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
    Oelze M; Kröller-Schön S; Welschof P; Jansen T; Hausding M; Mikhed Y; Stamm P; Mader M; Zinßius E; Agdauletova S; Gottschlich A; Steven S; Schulz E; Bottari SP; Mayoux E; Münzel T; Daiber A
    PLoS One; 2014; 9(11):e112394. PubMed ID: 25402275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress.
    Bugga P; Mohammed SA; Alam MJ; Katare P; Meghwani H; Maulik SK; Arava S; Banerjee SK
    Life Sci; 2022 Oct; 307():120862. PubMed ID: 35934058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.